

Leyden Labs Acquires RIGImmune

Client News

September 9, 2026

Gunderson Dettmer represented RIGImmune in its acquisition by Leyden Labs.

RIGImmune is a biopharmaceutical company developing a new class of immune modulating therapies for diseases caused by RNA viruses and for antitumor immune response induction. Completed earlier this year, Leyden Labs' acquisition of RIGImmune added its RIG-101 and proprietary NEED™ (Nano-Emulsion Effective Delivery) intranasal delivery platform to the company's growing portfolio of airway-targeted medicines. The acquisition will support Leyden Labs' efforts to protect vulnerable populations from airborne viral infections.

The announcement of the acquisition comes as Leyden Labs reports positive Phase 1 results for RIG-101, an intranasal therapy initially being studied to prevent virus-triggered asthma exacerbations by strengthening natural antiviral defenses. In the recently completed trial, RIG-101 was shown to be safe and well tolerated in healthy volunteers and patients with asthma.

"These Phase 1 results provide encouraging evidence that RIG-101 has the profile needed to advance into Phase 2 patient studies," said Susan Sobolov, CTO of Leyden Labs and former President and COO of RIGImmune, [in the announcement of the acquisition](#). "We believe the enhancement of innate antiviral response represents a promising new therapeutic strategy for the prevention of a broad range of respiratory viral infections in vulnerable patients with chronic airway disease."

The Gunderson deal team was led by Tim Ehrlich and Tim Kulis and included Alex Bloom, Bennett Evans, Lily Kim, Ray Fang, Emily Cabrera, and Mark Macchi.

Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Timothy J. Kulis

PARTNER

P +1 617 648 9236

Alex Bloom

ASSOCIATE

P +1 617 648 9272

Bennett Evans

ASSOCIATE

P +1 617 648 9251

Lily H. Kim

PARTNER

P +1 650 463 5326

Ray Fang

ASSOCIATE

P +1 415 801 4855

Emily E. Cabrera

PARTNER

P +1 212 430 4201

Mark Macchi

ASSOCIATE

P +1 617 648 9383

Related Services

Life Sciences

Mergers & Acquisitions

Private & Public Companies

Featured Insights

EVENTS

Webinar: Taking a Company Public: Lessons from IPO-Tested GCs

CLIENT NEWS

Gunderson Dettmer Advises Zola on Definitive Agreement to Be Acquired by The Knot Worldwide

CLIENT NEWS

Phinity Labs Emerges From Stealth With \$5.2 Million Seed

CLIENT NEWS

TCGX Announces Oversubscribed \$600 Million Asia Fund

CLIENT NEWS

Hims & Hers Co-Leads Arboretum's \$30 Million Series A

CLIENT NEWS

Reuse Raises \$21 Million Series A

PUBLIC VENTURES

SEC Staff Grants Broad Relief for Board-Aligned Retail Shareholder Voting Programs

CLIENT NEWS

Andreessen Horowitz Leads Armadin's Series B

CLIENT NEWS

Parafin Announces Agreement to Be Acquired by Stripe

FIRM NEWS

Gunderson Dettmer Launches Inaugural Client Development Accelerator

CLIENT NEWS

Limited Raises \$18.5 Million Seed

INSIGHTS

Client Insight: AI Tools and Confidentiality: Practical Guidance for Companies for Protection Under Attorney-Client Privilege and Work-Product Doctrine